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Background: Merkel cell polyomavirus (MCPyV) was identified originally in Merkel cell carcinoma (MCC), a rare form
of human skin neuroendocrine carcinoma. Evidence of MCPyV existence in other forms of malignancy such as
cutaneous squamous cell carcinomas (SCCs) is growing. Cervical cancers became the focus of our interest in
searching for potentially MCPyV-related tumors because: (i) the major histological type of cervical cancer is the SCC;
(ii) the uterine cervix is a common site of neuroendocrine carcinomas histologically similar to MCCs; and (iii) MCPyV
might be transmitted during sexual interaction as demonstrated for human papillomavirus (HPV). In this study, we
aimed to clarify the possible presence of MCPyV in cervical SCCs from Japanese patients. Cervical adenocarcinomas
(ACs) were also studied.
Results: Formalin-fixed paraffin-embedded tissue samples from 48 cervical SCCs and 16 cervical ACs were
examined for the presence of the MCPyV genome by polymerase chain reaction (PCR) and sequencing analyses.
PCR analysis revealed that 9/48 cervical SCCs (19%) and 4/16 cervical ACs (25%) were positive for MCPyV DNA.
MCPyV-specific PCR products were sequenced to compare them with reference sequences. The nucleotide
sequences in the MCPyV large T (LT)-sequenced region were the same among MCPyV-positive cervical SCCs and
AC. Conversely, in the MCPyV viral protein 1 (VP1)-sequenced region, two cervical SCCs and three cervical ACs
showed several nucleotide substitutions, of which three caused amino acid substitutions. These sequencing results
suggested that three MCPyV variants of the VP1 were identified in our cases. Immunohistochemistry showed that
the LT antigen was expressed in tumor cells in MCPyV-positive samples. Genotyping of human HPV in the MCPyV-
positive samples revealed that infected HPVs were HPV types 16, 31 and 58 for SCCs and HPV types 16 and 18 for
ACs.
Conclusions: This study provides the first observation that MCPyV coexists in a subset of HPV-associated cervical
cancers from Japanese patients. The prevalence of MCPyV in these lesions was close to that observed in the
cutaneous SCCs. Further worldwide epidemiological surveys are warranted to determine the possible association of
MCPyV with pathogenesis of cervical cancers.
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Polyomaviruses are small, nonenveloped DNA viruses with
icosahedral capsids containing a circular double-stranded
DNA genome. Merkel cell polyomavirus (MCPyV) was
discovered in Merkel cell carcinoma (MCC) [1]. MCC is a
rare but aggressive neuroendocrine carcinoma of the skin,
characterized by the common clinical features known as
“AEIOU”: namely, asymptomatic, expanding rapidly, im-
munosuppressive, occurring in patients older than 50 years
and located in ultraviolet-exposed sites [2]. Subsequent
studies confirmed a more frequent prevalence of MCPyV
in MCCs from North American and European patients
than in Australian patients [3-15]. Among Asian patients,
MCPyV has been shown to be present in 55–79% of MCCs
in Japan [16-18].
The MCC tumor is probably derived from primitive epi-
dermal stem cells [19], but its origin is still controversial.
Conversely, its fine structure has been well studied and
immunohistochemistry is important for diagnosing MCCs
as they express both epithelial and neuroendocrine markers
[20]. Among these, cytokeratin (CK) 20, a cytoskeleton of
intermediate filaments, is the most specific and sensitive
marker for detecting MCCs [21]. This immunophenotype
has been reported for some cervical neuroendocrine carcin-
omas [22]. However, in that report, all CK20-positive cases
showed a negative reaction with CM2B4, a monoclonal
antibody against an antigenic epitope on the MCPyV large
T (LT) antigen [23]. Since then, the association of MCPyV
with cervical cancers has not been studied.
The route of MCPyV transmission has not been estab-
lished, but MCPyV was detected in respiratory tractTable 1 Summary of clinicopathological data and results of P
MCPyV DNA-positive cases
Case Clinical information PCR
Type Age Stage* MCPyV LTsh MCPyV VP1 HP
1 SCC 45 IIa + –
3 SCC 74 IIb + +
30 SCC 29 0 + –
31 SCC 42 0 + –
35 SCC 59 Ia + –
36 SCC 38 0 + –
39 SCC 33 0 + –
47 SCC 38 Ia – +
48 SCC 46 Ia + –
6 AC 50 Ib – +
7 AC 61 Ib – +
15 AC 54 Ib + –
16 AC 72 Ib – +
*According to the FIGO clinical staging.
†Immunohistochemistry with CM2B4 monoclonal antibody.secretions [24-27]. If MCPyV is transmitted during sexual
activity, it is conceivable that the uterine cervix would be
exposed to this virus. In fact, MCPyV was also detected in
the oral and anogenital mucosa of human immunodefi-
ciency virus-positive individuals [28,29]. These findings
prompted us to investigate the existence of MCPyV in cer-
vical cancers.
The cutaneous squamous cell carcinoma (SCC) is the
second most frequent skin cancer [30]. MCCs can arise
as a population admixed with SCC cells in the same le-
sion [31-33]. MCPyV has also been detected in cutane-
ous SCCs at a lower frequency than MCCs [34-37]. Our
previous study showed that MCPyV was present in 13%
of cutaneous SCCs from Japanese patients [38].
The major histological type of cervical cancer is the SCC
in which human papillomavirus (HPV) is recognized as a
causative agent. The aims of this study were to investigate
whether MCPyV exists in cervical SCCs, as seen in cutane-
ous SCCs from Japanese patients. Cervical adenocarcinomas
(ACs) were also examined for the existence of MCPyV.
Results
Detection of MCPyV DNA
Formalin-fixed paraffin-embedded (FFPE) resection speci-
mens from 48 Japanese cervical SCCs (denoted as cases
SCC1 to SCC48) and 16 cervical ACs (cases AC1 to
AC16) were screened for the presence of MCPyV DNA by
polymerase chain reaction (PCR) analysis with two primer
sets targeting the MCPyV LT and viral protein 1 (VP1)
genes. The PCR results are summarized in Table 1. Of the
48 cervical SCCs, MCPyV DNA was detected in eightCR, real-time PCR and immunohistochemistry analyses in
Real-time PCR Immunohistochemistry
V type MCPyV DNA load
(copies per cell)
MCPyV LT† CK20 Chromogranin
16 0.00014 – – –
16 0.0013 2+ – –
16 0.00035 – – –
16 0.0021 – – –
58 0.00027 3+ – –
16 0.00033 1+ – –
58 0.00067 1+ – –
31 0.00073 – – –
16 0.00081 2+ – –
18 0.00064 – – –
16 0.00037 – – –
18 0.00095 3+ – –
16 0.0015 – – –
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primers and in two cases (SCC3 and 47) with the VP1 pri-
mers. Case SCC3 was positive for MCPyV with both the
VP1 and LTsh primers. Of 16 cervical ACs, MCPyV DNA
was detected in one case (AC15) with the LTsh primers
and in three cases (AC6, 7 and 16) with the VP1 primers.
Overall, nine cervical SCCs (19%) and four cervical ACs
(25%) were positive for MCPyV using either LTsh or VP1,
or both primers. The β-globin gene was amplified consist-
ently in all samples (data not shown). Clinical stages of the
patients with SCCs harboring MCPyV DNA were as fol-
lows: stage 0, 4 patients; Ia, 3 patients; IIa, 1 patient; and
IIb, 1 patient. The MCPyV genomes in patients with ACs
were all detected from samples at clinical stage Ib. The
MCPyV DNA-positive samples were all negative for CK20
and chromogranin by immunohistochemistry, indicating
the absence of a neuroendocrine immunophenotype
(Table 1).
MCPyV DNA sequencing
The PCR-positive products were sequenced to confirm
that they contained MCPyV-specific DNA and to compare
their results with reference sequences of the MCC350
genome isolated from cases of North American MCC [1]
and the TKS genome isolated from cases of Japanese
Kaposi sarcoma [16]. Eight cervical SCCs and one cervical
AC had identical nucleotide substitutions at positions 960
and 966 in the LT-sequenced region, followed by amino
acid substitutions (Figure 1). The nucleotide sequences
were also 100% homologous with that of TKS. Two cer-
vical SCCs and three cervical ACs showed the following
nucleotide substitutions in the VP1-sequenced region: T
instead of A at position 3994 in case AC7; C instead of T
at position 3972 in case AC6; A instead of G at position
3948 in cases AC7 and AC16; A instead of G at position
3919 in cases SCC3 and AC6; C instead of G at position
3875 in cases SCC3, SCC47 and AC6; and G instead of A
at position 3825 in all cases (Figure 2A). Of these, the nu-
cleotide substitutions at positions 3994, 3919, and 3875
caused amino acid substitutions (Figure 2B). Conse-
quently, one amino acid substitution was present at differ-
ent positions between cases SCC47 and AC7, whereas
cases SCC3 and AC6 shared a common amino acid
sequence. On the other hand, the nucleotide substitutions
in case AC16 did not result in amino acid substitutions.
Thus, three distinguishable variants of the VP1 were iden-
tified in our cases.
Quantification of MCPyV DNA
MCPyV DNA loads were determined in the PCR-positive
cases with either LTsh or VP1 primers. As shown in
Table 1, nine SCCs contained MCPyV DNA sequences
ranging from 0.00014 to 0.0021 copies per cell (median=
0.00067), while four ACs contained MCPyV DNAsequences ranging from 0.00037 to 0.0015 copies per cell
(median= 0.0008). These DNA loads were lower than
those in Japanese MCCs reported previously [17].
Expression of the MCPyV LT antigen
To evaluate the localization of MCPyV LT antigen ex-
pression, immunohistochemistry was performed using
the mouse monoclonal antibody CM2B4 or a rabbit
polyclonal antibody [23,39]. LT antigen is thought to be
associated with oncogenesis of MCPyV-positive MCCs
[40-43]. Semiquantitative immunohistochemistry find-
ings in MCPyV PCR-positive cases are summarized in
Table 1 and representative results are shown in Figure 3.
Diffuse or speckled nuclear signals were observed in
tumor cells, suggesting that these cancer cells harbored
the MCPyV genome. Although in some cases weak
staining was also observed in a small fraction of the ad-
jacent non-neoplastic components including epithelial
cells and lymphocytes, tumor cells had stronger nuclear
immunoreactivity. Six MCPyV PCR-negative samples
(three SCCs and three ACs) were also examined for the
expression of LT antigen by immunochemistry, but no
signals were detected (data not shown). Furthermore,
the isotype-matched negative control antibody for
CM2B4 showed no immunoreactivity either in cancer
cells or in the surrounding normal components.
Detection and typing of HPV DNA
The presence of the HPV L1 gene was confirmed in all
MCPyV-positive SCCs and ACs by PCR and by sequen-
cing analysis for HPV typing (Table 1). Of nine MCPyV-
positive SCCs, six cases were infected with HPV type 16,
two with HPV 58 and one with HPV 31. HPV type 16
(two cases) and HPV 18 (two cases) were also found
among the MCPyV-positive ACs.
Discussion
MCPyV is thought to play a role in MCC tumorigenesis
[1]. Although a causal link between MCPyV and other
types of malignancy has not been established to date, re-
cent studies have presented evidence of MCPyV detec-
tion in several cancers. Our previous findings showed
that MCPyV was present in 4/30 cutaneous SCCs (13%)
among Japanese patients [38]. A German group showed
that 7/28 cutaneous SCCs (25%) were positive for
MCPyV [35]. In other studies from North America, 26/
177 cutaneous SCCs (15%) and 2/15 SCCs (13%) were
positive for MCPyV [7,34]. Thus, the prevalence of
MCPyV in cutaneous SCCs has been confirmed among
distinct geographic populations. The present study
demonstrated that the prevalence of MCPyV in cervical
SCCs is close to that seen in cutaneous SCCs.
For detecting MCPyV, we used two primer sets targeting
the LT and VP1 regions, which gave different detection
AB
Figure 1 Multiple nucleotide alignments (A) and amino acid alignments (B) of the LT-sequenced region in cases positive for MCPyV
DNA with LTsh primers. Nucleotide substitutions are shown with gray boxes: C! T at position 960 in TKS and all cases; and G!A at position
966 in TKS and all cases. The two nucleotide substitutions resulted in amino acid substitutions (H! Y and A! T, respectively). Nucleotide
numbers refer to the sequence of MCC350 (GenBank accession number EU375803).
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ger amplicons by PCR of FFPE tissues, the LTsh primers
should have detected MCPyV in more cases than the VP1
primers. Otherwise, PCR amplification might be ham-
pered by mutations or deletions that exist in the primer
regions, as suggested by recent studies [9,40].
The occurrence of false positive PCR results is un-
likely. Our PCR runs were always performed using the
appropriate controls and the negative controls were con-
sistently negative in all experiments. To confirm that
the PCR products contained MCPyV-specific DNA
sequences but not artifacts, and to exclude the possibil-
ity of cross-contamination, we sequenced all the PCR
products. Obvious variations in the DNA sequences
were found in the MCPyV VP1 gene. The sequencing
results revealed the existence of three variants of the
VP1 in our cases. The amino acid substitutions were
present at three distinct positions, among which the re-
placement of glutamic acid with glutamine was found
previously between two North American isolates,
MCC350 and w162 [5]. Thus, amino acid substitutions
are likely to occur frequently in MCPyV. The same wasalso reported among French MCPyV isolates [14]. On
the other hand, amino acid substitutions at other loca-
tions would contribute to the antigenic diversity of the
Japanese MCPyV. Any potential role of these substitu-
tions remains to be elucidated.
We conducted immunohistochemistry of the MCPyV
DNA-positive cervical SCCs and ACs to study the
localization of MCPyV. CM2B4, a mouse monoclonal anti-
body to the MCPyV LT antigen, is available commercially
and has been used widely for immunohistochemistry. Re-
cently, a Japanese group generated a rabbit polyclonal anti-
body targeting a broader LT antigenic region than CM2B4
[39]. In addition to the CM2B4 monoclonal antibody, we
employed this polyclonal antibody for immunohistochemis-
try in some cases. Both antibodies resulted in homogeneous
or speckled nuclear staining of the tumor cells, indicating
that MCPyV exists in cervical cancer cells. Nonspecific
staining of the tissues is unlikely, because no signals were
detected in the MCPyV PCR-negative samples and because
our immunohistochemical method with the CM2B4 anti-
body was controlled by testing an isotype-matched control
antibody. However, in some cases, weak immunoreactivity
AB
Figure 2 Multiple nucleotide alignments (A) and amino acid alignments (B) of the VP1-sequenced region in cases positive for MCPyV
DNA with VP1 primers. Nucleotide substitutions resulting in amino acid substitutions are shown with gray boxes and the other nucleotide
substitutions are shown in boldface: A! T at position 3994 in case AC7; T!C at position 3972 in case AC6; G!A at position 3948 in cases AC7
and AC16; G!A at position 3919 in cases SCC3 and AC6; G!C at position 3875 in cases SCC3, SCC47 and AC6; G!A at position 3873 in TKS;
T!A at position 3831 in TKS; and A!G at position 3825 in TKS and all cases. Amino acid substitutions were D! V in case AC7, G! E in cases
SCC3 and AC6, and E!Q in cases SCC3, SCC47 and AC6.
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rounding normal cells. Therefore, we then performed PCR
using DNAs extracted from normal tissues of the same
patients with MCPyV PCR-positive cervical cancers, but
neither the LTsh nor VP1 primers detected MCPyV DNA
(data not shown). These findings suggest that the MCPyV
genome was also present in nonneoplastic tissues of the
uterine cervix at levels not detectable by PCR. The findings
of semiquantitative immunohistochemistry did not corres-
pond with the viral copy numbers detected by quantitative
real-time PCR. A possible interpretation on the results
would be that DNA in archived formalin-fixed tissues
might be fragmented in the primer-targeting gene areas,
and thereby the viral DNA copy numbers might be under-
estimated [44].
Currently, more than 100 HPV types have been identi-
fied and classified into high-risk and low-risk types
according to the probability of developing a cervical can-
cer [45]. The high-risk HPV types are regarded as majorcauses of cervical cancer. Compared with Southeast Asia,
Northern Africa, Europe and North America, HPV types
16 and 18 are less common and HPV types 31, 33, 52 and
58 are more common in Japanese patients with cervical
cancers [46]. In the present study, the high-risk HPV types
were detected predictably in all Japanese MCPyV-positive
samples. These were HPV types 16, 31 and 58 in MCPyV-
positive SCCs and HPV types 16 and 18 in MCPyV-
positive ACs. The HPV typing pattern suggested no direct
association of MCPyV with HPV types.
So far, research on the etiology of cervical cancers has
focused on HPV. The present study provides the first
evidence that MCPyV is present in a subset of HPV-
associated cervical cancers. Because the MCPyV LT anti-
gen is considered to be an oncoprotein responsible for the
MCPyV-dependent oncogenic pathway [40-43], expres-
sion of the MCPyV LT antigen in HPV-associated cervical
cancer cells suggests that MCPyV could be a cofactor of
HPV for tumor initiation and/or progression. In the
Figure 3 Immunohistochemistry for detecting the MCPyV LT antigen on cervical SCC and AC tissue sections. Hematoxylin and eosin
staining (A) showed histological findings of the specimens containing SCC cells (cases SCC3 and SCC35) and AC cells (case AC15).
Immunohistochemistry with the CM2B4 monoclonal antibody (B) and with the polyclonal antibody (D) showed immunoreactivity in the tumor
cells. Insets show higher magnification views of the tumor cells. The isotype-matched negative control antibody (mouse IgG2b) for CM2B4
showed no immunoreactivity (C).
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to be found at earlier clinical stages, although this needs
further study. Recently, Houben et al. [47] presented new
evidence that MCPyV might only be needed for tumor ini-
tiation, but additional mutations during tumor progression
render LT antigen expression dispensable for MCC car-
cinogenesis. Although we do not know yet whether
MCPyV is such a transient “hit and run” infectious patho-
gen or just a passenger during the development of cervical
cancer, our findings should stimulate further investigations
to clarify these important issues.
Conclusions
This is the first observation presenting data on the preva-
lence of MCPyV in cervical cancers from Japanese patients.
Our investigations indicate that MCPyV coexists in a subset
of HPV-associated cervical cancers. Further worldwide epi-
demiological surveys are warranted to determine the patho-
genetic relevance of MCPyV in cervical cancers.
Methods
Samples and DNA extraction
FFPE resection specimens were collected from the
archives of Kochi University Hospital. The average ages
of the patients with cervical SCCs and ACs were 43 years(range 28–74) and 54 years (range 41–80), respectively.
According to the International Federation of Gynecology
and Obstetrics (FIGO) clinical staging, the 48 SCC cases
included 21 patients with stage 0, 7 patients with Ia, 2
patients with Ib, 2 patients with IIa, 3 patients with IIb,
1 patient with IIIa, 7 patients with IIIb and 5 patients
with IVb. Of the 16 AC cases, there was 1 patient with
stage 0, 9 patients with Ib, 3 patients with IIb, 2 patients
with IIIb and 1 patient with IVb. All specimens were
inspected by two independent pathologists and proved
by histopathology to contain cancer cells. Two to five-
μm thick sections were obtained from each FFPE tissue
specimen and DNA was extracted using WaxFree DNA
Kits (TrimGen Corporation, Sparks, MD, USA) accord-
ing to the manufacturer’s instructions. This DNA was
used as a template for the PCR analysis. In some cases,
we also extracted DNA from non-neoplastic cervical
FFPE sections from the same patients with cervical can-
cers. This study was approved by the Ethics Committee
of Kochi Medical School, Kochi University (approval
number 2224).
Identification of MCPyV and HPV by PCR analysis
PCR was conducted with 200 ng of extracted DNA using
an AmpliTaq Gold 360 master mix (Life Technologies,
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ume of 50 μL. For detecting MCPyV DNA, two primer
sets designated LTsh and VP1 were employed (Table 2).
The LTsh primers were designed to detect a region of
exon 2 in the MCPyV LT gene. The forward and reverse
primers are located at nucleotide positions 910–930 and
1133–1152, respectively, based on the GenBank se-
quence EU375803. The VP1 primers target the MCPyV
VP1 gene region [1]. The GP5+/6+ primer set was used
to detect HPV DNA [48]. The β-globin gene was also
amplified in separate PCR runs as a positive control to
confirm the presence of PCR-amplifiable DNA. As a
PCR-negative control, water containing all PCR compo-
nents except for DNA was used. The reaction mixtures
were denatured at 95°C for 10 min and then amplified
with 40 cycles at 95°C for 30 s followed by 55°C for 30 s
for MCPyV, or 45°C for 30 s for HPV and 72°C for 30 s
for MCPyV, or 72°C for 10 s for HPV, with a final exten-
sion of 7 min at 72°C. The PCR products were electro-
phoresed on 2.5% agarose gels, visualized with ethidium
bromide staining and photographed using the Kodak
EDAS 290 gel documentation system (Kodak, Rochester,
NY, USA).
DNA sequencing analysis
The PCR products were purified with High Pure PCR
Product Purification Kits (Roche Diagnostics, Tokyo,
Japan) and then sequenced directly with ABI Big Dye
Terminator 1.1 Cycle Sequencing Kits (Life Technolo-
gies). The sequenced products were analyzed using a
model 3130 genetic system (Applied Biosystems, Tokyo,
Japan). For identifying HPV types, the obtained sequen-
cing data were BLAST searched using the NationalTable 2 Primer sequences used in this study
PCR analysis and DNA sequencing analysis
Target gene Primer name S
MCPyV LT LTsh-F G
LTsh-R C
MCPyV VP1 VP1-F T
VP1-R T
HPV L1 GP5+ T
GP6+ G
Human β-globin β-globin-F A
β-globin-R C
Real-time PCR analysis
Target gene Primer sequence (5’! 3’) P
MCPyV ST GCAAAAAAACTGTCTGACGTGG F
CCACCAGTCAAAACTTTCCCA
Human RNase P AGATTTGGACCTGCGAGCG F
GAGCGGCTGTCTCCACAAGTCenter for Biotechnology Information (NCBI) data-
base (http://www.ncbi.nlm.nih.gov/blast/Blast.cgi). The
MCPyV LT and VP1 sequencing data were aligned using
the BioEdit program and then compared with reference
sequences of the North American MCPyV isolate,
MCC350, and the Japanese MCPyV isolate, TKS (Gen-
Bank accession numbers EU375803 and FJ464337,
respectively).
Quantitative real-time PCR
Quantitative real-time PCR was conducted with 500 ng
of extracted DNA, according to the method of Bhatia
et al. [49] with some modifications. The primer and
probe sequences are shown in Table 2. Standard PCR
was conducted using the same primers and the PCR
product was cloned into the pMD20-T vector (TaKaRa,
Shiga, Japan). We prepared six-fold serial dilutions using
10 ng of the cloned plasmid DNA to generate a standard
curve and we calculated the copy number in each sam-
ple. The viral DNA load was defined as viral DNA copies
per RNase P gene copy, which represented the copy
number per cell.
Nucleotide sequence accession numbers
The obtained MCPyV LT and VP1 sequences were depos-
ited in the NCBI database under accession numbers
[AB645848, AB645849, AB645850, AB645851, AB645852,
AB645853, AB645854, AB645855, AB645856, AB645857,
AB645858, AB645859, AB645860, and AB645861].
Immunohistochemistry
For detecting MCPyV LT antigen expression, immuno-









robe sequence (5’! 3’)
AM-TATCAGTGCTTTATTCTTTGGTTTGGATTTCCTCCT-TAMRA
AM-TTCTGACCTGAAGGCTCTGCGCG-TAMRA
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type) [23] or a rabbit polyclonal antibody [39]. Samples
sectioned at 4 μm were deparaffinized and rehydrated.
Heat-induced epitope retrieval was performed using
EDTA antigen retrieval buffer for 30 min (Dako, Tokyo,
Japan). Endogenous peroxidase activity was blocked
using 3% hydrogen peroxide in water for 10 min. Fol-
lowing incubation with blocking solution for 10 min,
slides were incubated with the CM2B4 antibody diluted
with 0.05 mol/L Tris–HCl buffer containing 0.1% Tween
20 at 1:100 or with the rabbit polyclonal antibody at a
dilution of 1:2000 for 20 min at room temperature. After
sufficient washes in 0.05 mol/L Tris–HCl buffer solution
containing 0.3 mol/L NaCl, and 0.1% Tween 20 (TBST),
horseradish peroxidase-conjugated goat anti-mouse or
anti-rabbit immunoglobulin was applied as the second-
ary antibody for 15 min at room temperature. After fur-
ther washes in TBST, bindings of the primary antibodies
were detected using a biotin-free tyramide signal ampli-
fication system (Dako) according to the manufacturer’s
instructions. Finally, sections were counterstained with
hematoxylin. The specificity of staining with CM2B4
was controlled by testing an isotype-matched control
mouse IgG2b (Dako) in parallel.
Immunohistochemistry for detecting CK20 and chromo-
granin was performed as described [22]. For all immunohis-
tochemical markers, cases were scored as – (negative), 1+
(<10% cells immunoreactive), 2+ (10–50% cells immunor-
eactive), or 3+ (>50% cells immunoreactive).
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